Pub Date : 2020-07-07DOI: 10.20471/lo.2020.48.01.04
Ana Tečić-Vuger, R. Šeparović, L. Vazdar, M. Pavlovic, P. Lepetić, S. Šitić, B. Šarčević, D. Vrbanec
1Medical Oncology Department, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 2Department of Oncological Pathology and Clinical Cytology, Ljudevit Jurak University Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 3School of Medicine, University of Zagreb, Zagreb, Croatia; 4Medical School, University of Juraj Dobrila, Pula, Croatia
{"title":"Androgen receptors: unclear ubiquitious mechanism or the missing key in the triple–negative breast cancer?","authors":"Ana Tečić-Vuger, R. Šeparović, L. Vazdar, M. Pavlovic, P. Lepetić, S. Šitić, B. Šarčević, D. Vrbanec","doi":"10.20471/lo.2020.48.01.04","DOIUrl":"https://doi.org/10.20471/lo.2020.48.01.04","url":null,"abstract":"1Medical Oncology Department, Division for Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 2Department of Oncological Pathology and Clinical Cytology, Ljudevit Jurak University Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 3School of Medicine, University of Zagreb, Zagreb, Croatia; 4Medical School, University of Juraj Dobrila, Pula, Croatia","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2020.48.01.04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41784799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-07-07DOI: 10.20471/lo.2020.48.01.01
Ana Car-Peterko, M. Avirović, P. Valković-Zujić, Ingrid Belas-Lovasić, F. Lovasić
introduction: after the consensus conference in st. gallen and updated nccn guidelines, we started doing sentinel lymph node biopsy (slnB) in May 2017, for breast cancer patients who achieve clinical axillary remission following neoadjuvant treatment. this study’s primary goal was to evaluate the clinical impact of slnB after neoadjuvant therapy in the group mentioned above. Methods: We retrospectively analyzed all neoadjuvant breast cancer patients from May 2016 until May 2018 at clinical Hospital center rijeka. our preliminary results recorded the appearance of locoregional and distant recurrence. results: from 65 patients involved in this analysis, 48 patients were node-positive at the time of diagnosis, and 45.83% among those achieved complete pathological axillary remission. After the first postoperative year, there were no locoregional relapses nor statistically significant differences in the prevalence of distant recurrences, regardless of the extent of surgical procedure. However, results showed higher rates of locoregional and distant relapse for the group of patients that did not attain complete axillary remission. conclusion: slnB is a reliable alternative to alnD for locoregional and overall disease control for breast cancer patients who achieve complete clinical axillary remission after preoperative systemic treatment. the clinical axillary lymph node status, after neoadjuvant therapy, is a more relevant prognostic factor than the clinical axillary lymph node status at the beginning of the treatment. KeYWorDs: sentinel lymph node biopsy, neoadjuvant treatment, recurrence
{"title":"Clinical impact of sentinel lymph node biopsy after neoadjuvant treatment in breast cancer patients with initially involved axillary lymph nodes; single-center experience- preliminary analysis","authors":"Ana Car-Peterko, M. Avirović, P. Valković-Zujić, Ingrid Belas-Lovasić, F. Lovasić","doi":"10.20471/lo.2020.48.01.01","DOIUrl":"https://doi.org/10.20471/lo.2020.48.01.01","url":null,"abstract":"introduction: after the consensus conference in st. gallen and updated nccn guidelines, we started doing sentinel lymph node biopsy (slnB) in May 2017, for breast cancer patients who achieve clinical axillary remission following neoadjuvant treatment. this study’s primary goal was to evaluate the clinical impact of slnB after neoadjuvant therapy in the group mentioned above. Methods: We retrospectively analyzed all neoadjuvant breast cancer patients from May 2016 until May 2018 at clinical Hospital center rijeka. our preliminary results recorded the appearance of locoregional and distant recurrence. results: from 65 patients involved in this analysis, 48 patients were node-positive at the time of diagnosis, and 45.83% among those achieved complete pathological axillary remission. After the first postoperative year, there were no locoregional relapses nor statistically significant differences in the prevalence of distant recurrences, regardless of the extent of surgical procedure. However, results showed higher rates of locoregional and distant relapse for the group of patients that did not attain complete axillary remission. conclusion: slnB is a reliable alternative to alnD for locoregional and overall disease control for breast cancer patients who achieve complete clinical axillary remission after preoperative systemic treatment. the clinical axillary lymph node status, after neoadjuvant therapy, is a more relevant prognostic factor than the clinical axillary lymph node status at the beginning of the treatment. KeYWorDs: sentinel lymph node biopsy, neoadjuvant treatment, recurrence","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43050089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-07-07DOI: 10.20471/lo.2020.48.01.05
Martina Mikulandra, Iva Andrašek, L. Beketić-Orešković
The abscopal effect is a phenomenon that describes the systemic antitumor response that can occur as a result of a localized radiotherapy. Although sporadic cases of abscopal effect have been reported since 1960’s, the number of reported cases are significantly increasing in the immunotherapy era. Immunotherapy seems to enhance the immunogenic effects of radiotherapy, thus increasing systemic antitumor response. Although combination of radiotherapy and immunotherapy is a promising strategy in the treatment of metastatic cancers, many questions regarding the optimal treatment remain unanswered. Increasing number of ongoing studies will hopefully provide answers to these questions, enabling the utilization of this strategy in systemic anticancer treatment.
{"title":"Abscopal effect of radiotherapy: an old concept in a new era","authors":"Martina Mikulandra, Iva Andrašek, L. Beketić-Orešković","doi":"10.20471/lo.2020.48.01.05","DOIUrl":"https://doi.org/10.20471/lo.2020.48.01.05","url":null,"abstract":"The abscopal effect is a phenomenon that describes the systemic antitumor response that can occur as a result of a localized radiotherapy. Although sporadic cases of abscopal effect have been reported since 1960’s, the number of reported cases are significantly increasing in the immunotherapy era. Immunotherapy seems to enhance the immunogenic effects of radiotherapy, thus increasing systemic antitumor response. Although combination of radiotherapy and immunotherapy is a promising strategy in the treatment of metastatic cancers, many questions regarding the optimal treatment remain unanswered. Increasing number of ongoing studies will hopefully provide answers to these questions, enabling the utilization of this strategy in systemic anticancer treatment.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2020.48.01.05","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49188126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-29DOI: 10.20471/lo.2019.47.02-03.15
Brigita Vilč, Ana Šečić, I. Kirac, I. Herman, Nada Kraljević, Senija Brnić
Summary a comprehensive approach is essential in treating cancer patients, precisely because of the complexity and long duration of medical treatment, which involves lengthy and often painful and exhausting medical procedures that often cause different consequences. The diagnosis of cancer, surgery, and (neo)adjuvant therapies such as chemotherapy or radiothera py also cause severe psychological and emotional distress. psychosocial oncology provides the use of supportive-comple-mentary as well as psychosocial interventions and methods as a form of a holistic approach during conventional medical treatment in cancer care, regardless of the stage of cancer or the current type of treatment. The apparent need for such type of cancer care also was demonstrated in University Hospital for Tumors, sestre milosrdnice University Hospital Centre in Zagreb, in the preoperative period and during radiotherapy through applying deep breathing exercises, relaxation techniques, guided imagery and music. In addition to achieving relaxation and adopting stress management methods, an es sential basis was a positive impact on the postoperative course as much as possible. The program included 315 hospitalized patients over the course of 8 months, and due to the possibility of repeated participation - with 478 patient sessions. The subjective participants` impression of the psychosocial oncology program was positive, with tendencies towards applying the adopted techniques even after hospitalization.
{"title":"Guided imagery and music in the preoperative period and during radiotherapy in University Hospital for Tumors, Sestre milosrdnice University Hospital Center in Zagreb, Croatia","authors":"Brigita Vilč, Ana Šečić, I. Kirac, I. Herman, Nada Kraljević, Senija Brnić","doi":"10.20471/lo.2019.47.02-03.15","DOIUrl":"https://doi.org/10.20471/lo.2019.47.02-03.15","url":null,"abstract":"Summary a comprehensive approach is essential in treating cancer patients, precisely because of the complexity and long duration of medical treatment, which involves lengthy and often painful and exhausting medical procedures that often cause different consequences. The diagnosis of cancer, surgery, and (neo)adjuvant therapies such as chemotherapy or radiothera py also cause severe psychological and emotional distress. psychosocial oncology provides the use of supportive-comple-mentary as well as psychosocial interventions and methods as a form of a holistic approach during conventional medical treatment in cancer care, regardless of the stage of cancer or the current type of treatment. The apparent need for such type of cancer care also was demonstrated in University Hospital for Tumors, sestre milosrdnice University Hospital Centre in Zagreb, in the preoperative period and during radiotherapy through applying deep breathing exercises, relaxation techniques, guided imagery and music. In addition to achieving relaxation and adopting stress management methods, an es sential basis was a positive impact on the postoperative course as much as possible. The program included 315 hospitalized patients over the course of 8 months, and due to the possibility of repeated participation - with 478 patient sessions. The subjective participants` impression of the psychosocial oncology program was positive, with tendencies towards applying the adopted techniques even after hospitalization.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.02-03.15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49212872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-29DOI: 10.20471/lo.2019.47.02-03.19
Iva Andrašek, M. Ravlić, F. Cmrečak, D. Orešković, Sabina Deveđija, L. Beketić-Orešković
1Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 2Department of Neurosurgery, University Hospital Dubrava, Zagreb, Croatia; 3Department of Neurology, University Hospital Dubrava, Zagreb, Croatia; 4Department of Clinical Oncology, School of Medicine University of Zagreb and Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
{"title":"Oncological emergencies","authors":"Iva Andrašek, M. Ravlić, F. Cmrečak, D. Orešković, Sabina Deveđija, L. Beketić-Orešković","doi":"10.20471/lo.2019.47.02-03.19","DOIUrl":"https://doi.org/10.20471/lo.2019.47.02-03.19","url":null,"abstract":"1Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; 2Department of Neurosurgery, University Hospital Dubrava, Zagreb, Croatia; 3Department of Neurology, University Hospital Dubrava, Zagreb, Croatia; 4Department of Clinical Oncology, School of Medicine University of Zagreb and Division of Radiotherapy and Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.02-03.19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67598477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-29DOI: 10.20471/lo.2019.47.02-03.16
M. Šekerija, Maša Alfirević, Uršula Fabijanić, N. Rajačić, N. Antoljak
Summary Cancer is a major public health issue worldwide. It is very important to have high-quality epidemiological data to plan the measures in primary, secondary and tertiary prevention, to benchmark in comparison to other countries and to assess trends for particular cancer sites. This paper presents the basic epidemiology indicators for Croatia, explains the concepts surrounding the data collection and analytical procedures for essential epidemiological parameters and presents the most recent data, estimates and comparisons in the advent of the first Croatian National Cancer Plan.
{"title":"Epidemiology of cancer in Croatia – recent insights and international comparisons","authors":"M. Šekerija, Maša Alfirević, Uršula Fabijanić, N. Rajačić, N. Antoljak","doi":"10.20471/lo.2019.47.02-03.16","DOIUrl":"https://doi.org/10.20471/lo.2019.47.02-03.16","url":null,"abstract":"Summary Cancer is a major public health issue worldwide. It is very important to have high-quality epidemiological data to plan the measures in primary, secondary and tertiary prevention, to benchmark in comparison to other countries and to assess trends for particular cancer sites. This paper presents the basic epidemiology indicators for Croatia, explains the concepts surrounding the data collection and analytical procedures for essential epidemiological parameters and presents the most recent data, estimates and comparisons in the advent of the first Croatian National Cancer Plan.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.02-03.16","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48132078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-29DOI: 10.20471/lo.2019.47.02-03.08
Darko Kotromanović, Z. Kotromanović, Ilijan Tomaš, Josipa Flam, Sonja Kotromanović, Ž. Kotromanović, Mirela Penc-Šambić
Summary Objectives : The purpose of the study was to determine the difference in time until the appearance of relapse or metas tases in patients treated for colorectal cancer, depending on the location of the tumor in the left or right colon at the oncology clinic of clinical Medical centre osijek between 1 st January 2010 and 31 st December 2012. Study design : historical prospective study Material and methods : study included patients whose data were recorded from medical archive at the oncology clinic of Clinical Medical Centre Osijek. The data on patients’ deaths were recorded from the Registry Office of the Republic of croatia. Results : the study included 272 patients, 160 (58.8%) men and 112 (41.2%) women. according to the location, left sided colon tumor was discovered in 211 (77.6%) patients and right-sided in 61 (22.4%). the median age was 67 years. right-sided colon tumors are considerably larger with median diameter of 6 cm, with median number of 16. Median of time until the appearance of the metastases is 20 months (interquartile range is from 8 to 29 months); marked time being shorter in right-sided colon tumors. Positive outcome of the treatment was achieved in 205 (75.4%) patients, with no significant difference in com parison to the colon cancer localization. By using Kaplan-Meier analysis of patients’ survival rates, a total 5- year survival rate of 72% was achieved in right-sided colon tumor in comparison to 62% in patients with the left-sided colon tumor. Conclusion : This study confirms that there is a difference in colorectal cancer according to its localisation. Patients with right-sided colorectal cancer are older, the carcinoma is larger, the time until the appearance of a relapse or a metastases is shorter in right sided colon cancer while 5-year survival rate is lower in left sided colon cancer.
{"title":"The difference between left and right colon cancer patients’ characteristics - single center experience","authors":"Darko Kotromanović, Z. Kotromanović, Ilijan Tomaš, Josipa Flam, Sonja Kotromanović, Ž. Kotromanović, Mirela Penc-Šambić","doi":"10.20471/lo.2019.47.02-03.08","DOIUrl":"https://doi.org/10.20471/lo.2019.47.02-03.08","url":null,"abstract":"Summary Objectives : The purpose of the study was to determine the difference in time until the appearance of relapse or metas tases in patients treated for colorectal cancer, depending on the location of the tumor in the left or right colon at the oncology clinic of clinical Medical centre osijek between 1 st January 2010 and 31 st December 2012. Study design : historical prospective study Material and methods : study included patients whose data were recorded from medical archive at the oncology clinic of Clinical Medical Centre Osijek. The data on patients’ deaths were recorded from the Registry Office of the Republic of croatia. Results : the study included 272 patients, 160 (58.8%) men and 112 (41.2%) women. according to the location, left sided colon tumor was discovered in 211 (77.6%) patients and right-sided in 61 (22.4%). the median age was 67 years. right-sided colon tumors are considerably larger with median diameter of 6 cm, with median number of 16. Median of time until the appearance of the metastases is 20 months (interquartile range is from 8 to 29 months); marked time being shorter in right-sided colon tumors. Positive outcome of the treatment was achieved in 205 (75.4%) patients, with no significant difference in com parison to the colon cancer localization. By using Kaplan-Meier analysis of patients’ survival rates, a total 5- year survival rate of 72% was achieved in right-sided colon tumor in comparison to 62% in patients with the left-sided colon tumor. Conclusion : This study confirms that there is a difference in colorectal cancer according to its localisation. Patients with right-sided colorectal cancer are older, the carcinoma is larger, the time until the appearance of a relapse or a metastases is shorter in right sided colon cancer while 5-year survival rate is lower in left sided colon cancer.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.02-03.08","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41562253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-29DOI: 10.20471/lo.2019.47.02-03.14
Z. Misir, S. Jankovic, M. Šekerija, J. Filipović-Čugura, Burim Muhaxhiri, I. Kirac
Summary Gastric is considered neglected cancer in terms of stage at diagnosis and success of treatment worldwide. Early detec tion and quality of gastric cancer surgery remain the most important for successful treatment in terms of overall survival. In this paper, we focus on the overview of hospitals and volume of gastric cancer in Croatia as a possible baseline for quality assessment and implementation of existing quality guidelines. We accessed publicly available data from the Croatian Insur ance Fund for the period between 1st January 2013 to 31st December 2018. For background information on gastric cancer incidence and mortality, we used Croatian Cancer Registry data available online. We obtained both the number of resected gastric cancer in all Croatian hospitals as well as the length of stay. Data analysis discovered that there is a clear volume difference between teaching hospitals and non-teaching hospitals; only the first have sufficient volume for quality audit. This overview stresses one of the most critical points in cancer surgery, volume of surgery as a quality indicator.
{"title":"Overview of surgical gastric cancer treatment according to the hospital volume in Croatia","authors":"Z. Misir, S. Jankovic, M. Šekerija, J. Filipović-Čugura, Burim Muhaxhiri, I. Kirac","doi":"10.20471/lo.2019.47.02-03.14","DOIUrl":"https://doi.org/10.20471/lo.2019.47.02-03.14","url":null,"abstract":"Summary Gastric is considered neglected cancer in terms of stage at diagnosis and success of treatment worldwide. Early detec tion and quality of gastric cancer surgery remain the most important for successful treatment in terms of overall survival. In this paper, we focus on the overview of hospitals and volume of gastric cancer in Croatia as a possible baseline for quality assessment and implementation of existing quality guidelines. We accessed publicly available data from the Croatian Insur ance Fund for the period between 1st January 2013 to 31st December 2018. For background information on gastric cancer incidence and mortality, we used Croatian Cancer Registry data available online. We obtained both the number of resected gastric cancer in all Croatian hospitals as well as the length of stay. Data analysis discovered that there is a clear volume difference between teaching hospitals and non-teaching hospitals; only the first have sufficient volume for quality audit. This overview stresses one of the most critical points in cancer surgery, volume of surgery as a quality indicator.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.02-03.14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48742638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-29DOI: 10.20471/lo.2019.47.02-03.13
Marko Bebek, M. Baučić, S. Šandrk, M. Gnjidić, M. Gamulin
SUMMARY forty two to 57% of patients with metastatic renal cell carcinoma (mrCC) receive the second-line therapy according to available data. in our analysis we wanted to determine the percentage of patients within intermediate/poor prognostic group mRCC who continued the treatment with the second line following progression on the first line and the percentage of patients who were not able to receive the second line treatment. Patients received sunitinib (first started on 12 August 2018) or pazopanib (first started on May 2014) at University Hospital Center Zagreb. The latest treatment started in Decem ber 2018. our results show that 39.4% of patients who received sunitinib and 37.9% of patients who received pazopanib, did not receive the second line treatment, which is consistent with available data. The question arises whether we could have helped those patients if we had access to newer therapeutic options.
{"title":"Analysis of intermediate and poor prognostic group of patients with metastatic kidney cancer treated at the University Hospital Center Zagreb","authors":"Marko Bebek, M. Baučić, S. Šandrk, M. Gnjidić, M. Gamulin","doi":"10.20471/lo.2019.47.02-03.13","DOIUrl":"https://doi.org/10.20471/lo.2019.47.02-03.13","url":null,"abstract":"SUMMARY forty two to 57% of patients with metastatic renal cell carcinoma (mrCC) receive the second-line therapy according to available data. in our analysis we wanted to determine the percentage of patients within intermediate/poor prognostic group mRCC who continued the treatment with the second line following progression on the first line and the percentage of patients who were not able to receive the second line treatment. Patients received sunitinib (first started on 12 August 2018) or pazopanib (first started on May 2014) at University Hospital Center Zagreb. The latest treatment started in Decem ber 2018. our results show that 39.4% of patients who received sunitinib and 37.9% of patients who received pazopanib, did not receive the second line treatment, which is consistent with available data. The question arises whether we could have helped those patients if we had access to newer therapeutic options.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.02-03.13","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48273802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-29DOI: 10.20471/lo.2019.47.02-03.12
K. Katić, V. Matković, J. Lešin, Goran Vujić, Pavao Planinić, A. Ćorušić
Epithelial ovarian cancer is the seventh most common cancer among women and the leading cause of gynecological cancer related deaths in Croatia. Approximately 70% of patients are diagnosed at an advanced stage of the disease (FIGO III and IV). The usual approach to treatment involves complete surgical cytoreduction (R0), followed by combined platinumbased chemotherapy. Bevacizumab is recommended to add to paclitaxel/carboplatin chemotherapy in patients diagnosed at FIGO IIIB and IIIC stage with residual disease after surgery and all patients FIGO IV stage of disease, which can extend the time to progression of the disease in these patients.
{"title":"First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab - our experience","authors":"K. Katić, V. Matković, J. Lešin, Goran Vujić, Pavao Planinić, A. Ćorušić","doi":"10.20471/lo.2019.47.02-03.12","DOIUrl":"https://doi.org/10.20471/lo.2019.47.02-03.12","url":null,"abstract":"Epithelial ovarian cancer is the seventh most common cancer among women and the leading cause of gynecological cancer related deaths in Croatia. Approximately 70% of patients are diagnosed at an advanced stage of the disease (FIGO III and IV). The usual approach to treatment involves complete surgical cytoreduction (R0), followed by combined platinumbased chemotherapy. Bevacizumab is recommended to add to paclitaxel/carboplatin chemotherapy in patients diagnosed at FIGO IIIB and IIIC stage with residual disease after surgery and all patients FIGO IV stage of disease, which can extend the time to progression of the disease in these patients.","PeriodicalId":53700,"journal":{"name":"Libri Oncologici","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.20471/lo.2019.47.02-03.12","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43426673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：